Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data.

Destefano F, Pfeifer D, Nohynek H.

Bull World Health Organ. 2008 May;86(5):373-80. Review.

2.

Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).

Oosterhuis-Kafeja F, Beutels P, Van Damme P.

Vaccine. 2007 Mar 8;25(12):2194-212. Review.

PMID:
17267077
3.
4.

The safety of 7-valent pneumococcal conjugate vaccine.

Ghaffar F.

Expert Opin Drug Saf. 2005 Jul;4(4):631-6. Review.

PMID:
16011442
5.

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.

Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. Review.

PMID:
19325447
7.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
8.

Pneumococcal vaccine development.

Poolman JT.

Expert Rev Vaccines. 2004 Oct;3(5):597-604. Review.

PMID:
15485339
9.

Pneumococcal conjugate vaccines. A review.

Galiza EP, Heath PT.

Minerva Med. 2007 Apr;98(2):131-43. Review.

PMID:
17519855
10.

[Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].

de Greeff SC, Sanders EA, de Melker HE, van der Ende A, Vermeer PE, Schouls LM.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1454-7. Review. Dutch.

PMID:
17633974
11.

The potential indirect effect of conjugate pneumococcal vaccines.

O'Brien KL, Dagan R.

Vaccine. 2003 May 16;21(17-18):1815-25. Review.

PMID:
12706665
12.

Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efficacy against pneumonia and invasive disease.

Madhi SA, Whitney CG, Nohynek H.

Vaccine. 2008 Jun 16;26 Suppl 2:B9-B15. doi: 10.1016/j.vaccine.2008.06.001. Review.

PMID:
18793605
13.

Use of pneumococcal polysaccharide vaccines: no simple answers.

French N.

J Infect. 2003 Feb;46(2):78-86. Review.

PMID:
12634068
14.

Review of pneumococcal conjugate vaccine in adults: implications on clinical development.

Abraham-Van Parijs B.

Vaccine. 2004 Mar 29;22(11-12):1362-71. Review.

PMID:
15063558
15.

Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.

Rose M, Zielen S.

Expert Rev Vaccines. 2009 Oct;8(10):1351-64. doi: 10.1586/erv.09.78. Review.

PMID:
19803758
16.

Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV).

Croxtall JD, Keating GM.

Paediatr Drugs. 2009;11(5):349-57. doi: 10.2165/11202760-000000000-00000. Review.

PMID:
19725600
17.

Fever without source in children 0 to 36 months of age.

Ishimine P.

Pediatr Clin North Am. 2006 Apr;53(2):167-94. Review.

PMID:
16574521
18.

Safety and tolerability of pneumococcal vaccines in children.

Esposito S, Principi N.

Expert Opin Drug Saf. 2016 Jun;15(6):777-85. doi: 10.1517/14740338.2016.1160056. Review.

PMID:
26923347
19.

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia.

Loo JD, Conklin L, Fleming-Dutra KE, Deloria Knoll M, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S140-51. doi: 10.1097/INF.0000000000000082. Review.

20.

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

Beutels P, Thiry N, Van Damme P.

Vaccine. 2007 Feb 9;25(8):1355-67. Review.

PMID:
17208339
Items per page

Supplemental Content

Support Center